Abbott Laboratories

A class action lawsuit was filed in Illinois federal court against Abbott Laboratories and its subsidiary Exact Sciences over a data breach involving unauthorized access to patient information. The breach, attributed to cybercriminal group ShinyHunters via a voice phishing attack, exposed sensitive data including Social Security numbers, email addresses, and physical addresses from at-home cancer screening tests.

Healthcare company Abbott is investigating two cyber incidents involving unauthorized access to its Cancer Diagnostics business and LabCentral portal. Cybercriminal groups ShinyHunters and ShadowByt3$ claim extensive data breaches, including sensitive patient information, but Abbott denies significant impact on operations or data exposure.

Abbott Laboratories is investigating two cybersecurity incidents, including unauthorized access to internal legacy Exact Sciences systems in its Cancer Diagnostics business and a separate claim of a breach of its LabCentral portal leading to data theft.

Abbott Laboratories reported second-quarter profit of $928 million, with adjusted earnings of $1.31 per share, exceeding Wall Street's $1.28 per share estimate. The company also posted revenue of $12.59 billion, surpassing expectations of $12.48 billion. However, Abbott shares have fallen 29% this year and 32% in the last 12 months despite the strong earnings results.

Abbott Laboratories increased its 2026 profit guidance due to a stronger-than-expected second quarter driven by improved performance across most business lines.

Abbott Laboratories employees filed a class action lawsuit alleging the company offered two health insurance plans with identical coverage but significantly higher costs for the Traditional PPO option. The lawsuit claims Abbott violated the Employee Retirement Income Security Act by failing to meet its duty of prudence and objectivity in selecting health plans, as the more expensive option consistently imposed greater costs on employees without providing additional benefits.

A mother accused Mead Johnson's infant formula of causing her son's death from necrotizing enterocolitis (NEC), but the company concluded in an internal memo that the formula was not likely responsible. Mead Johnson closed the case without further investigation, and the FDA found no record of manufacturers reporting infant deaths linked to formula under regulatory requirements.

A whistleblower alleges that Abbott Laboratories bribed a Hawaiʻi provider, according to a lawsuit claiming the company defrauded federal health insurance programs.